TISIDB

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm.
Domain	PF00156 Phosphoribosyl transferase domain
Function	Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis.

> Gene Ontology [ TOP ]
Biological Process	GO:0006144 purine nucleobase metabolic process GO:0006164 purine nucleotide biosynthetic process GO:0006166 purine ribonucleoside salvage GO:0006167 AMP biosynthetic process GO:0006168 adenine salvage GO:0007589 body fluid secretion GO:0007595 lactation GO:0007625 grooming behavior GO:0009112 nucleobase metabolic process GO:0009113 purine nucleobase biosynthetic process GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009124 nucleoside monophosphate biosynthetic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009127 purine nucleoside monophosphate biosynthetic process GO:0009150 purine ribonucleotide metabolic process GO:0009152 purine ribonucleotide biosynthetic process GO:0009156 ribonucleoside monophosphate biosynthetic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009163 nucleoside biosynthetic process GO:0009165 nucleotide biosynthetic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009168 purine ribonucleoside monophosphate biosynthetic process GO:0009260 ribonucleotide biosynthetic process GO:0030879 mammary gland development GO:0032261 purine nucleotide salvage GO:0032868 response to insulin GO:0032869 cellular response to insulin stimulus GO:0032941 secretion by tissue GO:0042278 purine nucleoside metabolic process GO:0042440 pigment metabolic process GO:0042451 purine nucleoside biosynthetic process GO:0042455 ribonucleoside biosynthetic process GO:0043094 cellular metabolic compound salvage GO:0043096 purine nucleobase salvage GO:0043101 purine-containing compound salvage GO:0043173 nucleotide salvage GO:0043174 nucleoside salvage GO:0043434 response to peptide hormone GO:0044209 AMP salvage GO:0044708 single-organism behavior GO:0046033 AMP metabolic process GO:0046083 adenine metabolic process GO:0046084 adenine biosynthetic process GO:0046112 nucleobase biosynthetic process GO:0046128 purine ribonucleoside metabolic process GO:0046129 purine ribonucleoside biosynthetic process GO:0046148 pigment biosynthetic process GO:0046390 ribose phosphate biosynthetic process GO:0048732 gland development GO:0050878 regulation of body fluid levels GO:0071375 cellular response to peptide hormone stimulus GO:0071417 cellular response to organonitrogen compound GO:0072522 purine-containing compound biosynthetic process GO:1901293 nucleoside phosphate biosynthetic process GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1901657 glycosyl compound metabolic process GO:1901659 glycosyl compound biosynthetic process
Molecular Function	GO:0002054 nucleobase binding GO:0002055 adenine binding GO:0002060 purine nucleobase binding GO:0003999 adenine phosphoribosyltransferase activity GO:0016208 AMP binding GO:0016757 transferase activity, transferring glycosyl groups GO:0016763 transferase activity, transferring pentosyl groups
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00230 Purine metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-6798695: Neutrophil degranulation R-HSA-73847: Purine metabolism R-HSA-74217: Purine salvage

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between APRT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of APRT in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.83; FDR: 0.01650	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of APRT in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.394	0.183
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.174	0.959
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.561	0.811
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.183	0.739
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.069	0.969
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.502	0.822
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.109	0.785
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.533	0.726
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.294	0.868
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.045	0.985
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.551	0.879
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.009	0.913

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of APRT in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of APRT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of APRT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by APRT. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of APRT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of APRT expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between APRT and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	APRT
Name	adenine phosphoribosyltransferase
Aliases	AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting APRT collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting APRT.

ID	Name	Drug Type	Targets	#Targets
DB00173	Adenine	Small Molecule	ACACB, ACP1, APRT, MTAP, PECR, SRPK2	6
DB01632	Alpha-Phosphoribosylpyrophosphoric Acid	Small Molecule	APRT, HPRT1, UCKL1	3
DB03506	9-Deazaadenine	Small Molecule	APRT	1
DB04272	Citric Acid	Small Molecule	AKR1B1, ANG, APRT, BHMT, C8G, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A ......	23

Browse APRT